[Asia Economy Reporter Seo So-jeong] Samsung Bioepis announced on the 22nd that the sales of three autoimmune disease treatments in the European region in the third quarter increased by 13% compared to the same period last year.
According to the third-quarter results announced by Biogen, Samsung Bioepis's marketing partner in Europe, the third-quarter sales of Benepali (Enbrel biosimilar), Imraldi (Humira biosimilar), and Flixabi (Remicade biosimilar), developed by Samsung Bioepis, in the European market reached $207.9 million (approximately 243 billion KRW), significantly increasing from $183.6 million recorded in the same period last year.
In particular, Benepali, which surpassed cumulative product sales of 2 trillion KRW, achieved the number one market share in the entire European market, surpassing the original drug. Benepali's third-quarter product sales were $124.2 million (approximately 145 billion KRW), a 7% increase compared to the same period last year.
According to pharmaceutical market distribution data compiled by IQVIA, Benepali's market share in July reached 44%, surpassing the original drug and achieving first place for the first time in history.
Flixabi, the second product launched by Samsung Bioepis in Europe, achieved sales of $27.5 million (approximately 3.2 billion KRW) in the third quarter, a 49% increase compared to the same period last year. Imraldi, competing with five products including the original drug, recorded sales of $56.2 million (approximately 6.6 billion KRW) in the third quarter, a 14% increase compared to the same period last year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
